NCT01449019View on ClinicalTrials.gov

The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

July 31, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

exendin(9-39)amide

intravenous infusion of exendin(9-39)

DRUG

saline

intravenous infusion of saline

OTHER

duodenal meal

duodenal perfusion of a meal

OTHER

duodenal saline

duodenal perfusion of saline

Trial Locations (2)

80999

Ludwig Maximilians-University, Clinical Research Unit, Munich

81377

Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich, Munich

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER

NCT01449019 - The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter